Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Brain Neoplasms 5Meningeal Carcinomatosis 2Recurrence 1Rare Tumor 1Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1NSCLC 1Liver Diseases 1EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Docetaxel 4pembrolizumab 3Pemetrexed 3Nivolumab 2Cisplatin 2Carboplatin 2tislelizumab 1rofecoxib 1paclitaxel poliglumex 1osimertinib 1nazartinib 1lenvatinib 1cemiplimab 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Radiosurgery 1RO5126766 1Platinum Compounds 1Midazolam 1Gemcitabine 1Gefitinib 1Food 1Esomeprazole 1Drug Therapy 1Dabigatran 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × aumolertinib × Clear all
NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Qianfoshan Hospital

Phase 3 Recruiting
98 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡